BC Innovations | Apr 29, 2010
Finance

Beta testing in diabetes

Conventional wisdom holds that the only way to generate new islet cells in people with type 1 diabetes is through cell therapy. A trio of recent deals, however, suggests that some companies and not-for-profit organizations...
BC Week In Review | Sep 21, 2009
Clinical News

Exsulin: Phase II started

Exsulin began a double-blind, placebo-controlled, North American Phase II trial (E-201) to evaluate 100 or 200 mg subcutaneous Exsulin given thrice daily for 12 weeks in 27 patients who have been treated with insulin for...
BC Week In Review | Aug 24, 2009
Clinical News

Exsulin: Phase II data

The double-blind Phase II SPIRIT 2 trial in 126 patients with Type II diabetes showed that once-daily injections of 600 mg Exsulin missed the co-primary endpoint of significantly increasing arginine-stimulated C-peptide from baseline vs. placebo...
BC Week In Review | Aug 24, 2009
Clinical News

Exsulin: Phase II data

The double-blind Phase II SPIRIT 1 trial in 63 patients showed that once-daily injections of 600 mg Exsulin met the co-primary endpoint of significantly increasing arginine-stimulated C-peptide from baseline vs. placebo at day 56 (1.15...
BC Extra | Aug 19, 2009
Clinical News

Exsulin reports diabetes data

Exsulin Corp. (Minneapolis, Minn.) reported mixed results from a pair of double-blind Phase II trials of Exsulin to treat diabetes. In the SPIRIT 1 trial to treat Type I diabetes in 63 patients, once-daily injections...
BC Week In Review | May 12, 2008
Company News

DiaKine, Kinexum Metabolics Inc. deal

The companies partnered to develop a combination of DiaKine’s lisofylline and Kinexum’s islet neogenesis associated protein (INGAP) peptide to treat Type I diabetes. The companies will co-own the resulting product. Financial terms were not disclosed....
BC Week In Review | Apr 14, 2008
Clinical News

Cell Therapeutics, DiaKine preclinical data

In mice with Type I diabetes, treatment with Lisofylline followed by Lisofylline plus an islet neogenesis associated protein (INGAP) peptide led to a 70% complete remission rate and eliminated the need for insulin, Lisofylline or...
Items per page:
1 - 7 of 7